Conditions: Diabetes Diabetes Mellitus, Type 2
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 407
Healthy volunteers: no

Brief summary:
This trial is conducted in Asia, Europe and North America. The aim of the trial is to investigate the efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes not achieving adequate glycaemic control on sitagliptin and metformin.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: liraglutide intervention 2: sitagliptin intervention 3: placebo intervention 4: placebo
Intervention descriptions: intervention 1: Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered subcutaneously (s.c., under the skin) once daily + metformin tablets (at least 1000 mg/day) intervention 2: 100 mg/day sitagliptin tablets once-daily + metformin (at least 1000 mg/day) intervention 3: Sitagliptin placebo tablets once-daily intervention 4: Sitagliptin placebo tablets once-daily

Protocol document: